A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90048, United States
Metairie, Louisiana 70006, United States
Baltimore, Maryland 21231, United States
City of Saint Peters, Missouri 63376, United States
Creve Coeur, Missouri 63141, United States
Billings, Montana 59102, United States
Long Island City, New York 11101, United States
Philadelphia, Pennsylvania 19104, United States
Macquarie University, New South Wales 2109, Australia
Macquarie University, New South Wales 2109, Australia
East Bentleigh, Victoria 3165, Australia
East Bentleigh, Victoria 3165, Australia
Kelowna, British Columbia V1Y 5L3, Canada
Beer Yaakov, 70300, Israel
Beer Yaakov, 70300, Israel
Shiwa-gun, Iwate 028-3695, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Monterrey, Nuevo León 64460, Mexico
Amsterdam, North Holland 1066 CX, Netherlands
Tauranga Bay of Plenty, Tauranga 3112, New Zealand
Kursk, Kursk Oblast 305035, Russia
Saint Petersburg, Pesochny 197758, Russia
Saint Petersburg, Poselok Pesochniy 197758, Russia
Moscow, 105425, Russia
Nizhny Novgorod, 603126, Russia
Seongnam-si, Gyeonggido 13620, South Korea
Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
Manchester, M20 4BX, United Kingdom
Nottingham, NG5 1PB, United Kingdom